Co-founded by Carl June, MD, the Richard W. Vague Professor of Immunotherapy, and Jim Riley, PhD, Professor of Microbiology, at Penn Medicine, BlueWhale Bio successfully advanced its Synecta™ Cell-Derived Nanoparticle Platform (CDNP) for immune cell activation in 2025. Synecta mimics natural immune activation to produce higher-quality cells through simpler workflows. In September, the first patient was dosed in a University of Pennsylvania clinical trial using Synecta T1 CDNPs to streamline manufacturing of huCART19-IL18 cells for hematologic cancers. In October, BlueWhale and Avantor formed a partnership to produce GMP-grade CDNP materials and accelerate scale-up aimed at reducing CAR-T variability and shortening time-to-patient. The company also announced a collaboration with Kytopen to develop a non-viral workflow combining Synecta CDNPs with Flowfect® processing. In November, the FDA granted Synecta an Advanced Manufacturing Technology designation, enabling earlier FDA engagement and signaling confidence in scalable manufacturing. 

Dispatch Biotherapeutics is advancing a universal immunotherapy approach to treat solid tumors. Dispatch’s first-in-class Flare™ platform is engineered to overcome major barriers in solid tumor immunotherapy by tagging tumor cells with a synthetic antigen and altering local immunosuppressive mechanisms to boost immune targeting.The company co-founders include Carl June, MD, the Richard W. Vague Professor in Immunotherapy at Penn Medicine; Andy Minn, MD, PhD, Immuno-Oncology Program Chair at Memorial Sloan Kettering Cancer Center, formerly Penn faculty; and Lex Johnson PhD, Chief Platform Officer, formerly a Penn PhD student. Led by CEO, Saba Öney, Ph.D., the company publicly launched in July 2025 with the announcement that the company had raised $216 million since its founding in 2022. In November, Dispatch announced a clinical supply and collaboration agreement with Bristol Myers Squibb, and shared preclinical data at the Society for Immunotherapy of Cancer 2025 Annual Meeting supporting its Flare platform and its first therapeutic program, DISP-10, for targeting solid tumors. Dispatch plans to initiate a first-in-human Phase 1 study in 2026. 

GEMMABio is a global genetic medicines company founded by James Wilson, MD, PhD, Emeritus Professor of Medicine at Penn Medicine, focused on advancing and expanding access to life-changing gene therapies for rare and ultra-rare diseases. In 2025, the company achieved a major milestone after receiving clearance from the health regulatory agency in Brazil to initiate clinical trials of GB221, its next-generation gene therapy for spinal muscular atrophy type 1 (SMA1). GB221 is a one-time AAV-based therapy delivered directly to the central nervous system and is designed to restore functional SMN1 expression while reducing neurotoxicity, systemic exposure, and cost of goods. Brazil also serves as a strategic regional hub for GEMMABio through a public-private partnership with the Oswaldo Cruz Foundation (Fiocruz), including technology transfer for local vector manufacturing to support affordability and access. In parallel, GEMMABio launched Rare Therapeutics, Inc., a clinical-stage affiliate dedicated to advancing gene therapies for ultra-orphan diseases such as GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy.  

MavriX Bio is a clinical-stage biotechnology company developing genetic medicines for Angelman syndrome and other severe neurological disorders with high unmet need, based on technology developed by James Wilson, MD, PhD, Emeritus Professor of Medicine at Penn Medicine. The company’s lead program, MVX-220, is an investigational adeno-associated virus (AAV) gene therapy designed to restore functional UBE3A expression in neurons, targeting the root cause of Angelman syndrome. The FDA cleared MavriX’s IND for MVX-220 in May 2025, enabling initiation of the Phase 1/2 ASCEND-AS first-in-human study in adults and pediatric participants across multiple genotypes. In September 2025, MVX-220 received FDA Fast Track designation, and in November 2025, MavriX reported dosing the first participant in the ASCEND-AS Trial and received FDA Orphan Drug Designation.  

REGENXBIO is a leading gene therapy company co-founded by James M. Wilson, MD, PhD, Emeritus Professor of Medicine at Penn Medicine. In 2025, the company reached significant regulatory, clinical, and manufacturing milestones across its late-stage pipeline targeting rare pediatric diseases. The FDA granted Priority Review to the Biologics License Application for RGX-121 for the treatment of Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome, advancing the program toward a potential first one-time treatment for the disorder. A strategic commercialization partnership was also announced in January 2025 with NS Pharma, Inc. In September 2025, the company shared new data from the Phase I/II/III CAMPSIITE® trial of RGX-121, with positive neurodevelopmental outcomes observed in the pivotal and dose-finding phases of the trial. REGENXBIO also reported continued progress for RGX-202, its investigational gene therapy for Duchenne muscular dystrophy, including positive interim clinical results from the AFFINITY DUCHENNE® trial and completion of enrollment in the pivotal study as of October 2025.  

Co-founded by Stefanie Modri, MSN, RNC-MNN, C-OB, Clinical Adjunct Professor of Nursing at  Penn Nursing, James Weimer, PhD, Assistant Professor of Computer Science at Vanderbilt University, and Christine Rohan, MBA, CEO,  Vasowatch is developing a Software as a Medical Device (SaMD) platform to enable early prediction and prevention of postpartum hemorrhage, a leading cause of maternal morbidity and mortality worldwide. Its wearable-agnostic VIBRANT algorithm integrates with existing hospital equipment and is a scalable and affordable solution to deliver objective, real-time risk assessment, addressing limitations of subjective clinical measurement. In June 2025, Vasowatch presented VIBRANT’s predictive framework at the CHASE 2025 ACM/IEEE International Conference on Connected Health. The company participated in and presented at numerous conferences and pitch competitions, winning several prizes and strengthening relationships with stakeholders in both the clinical and investor communities.  

Looking ahead to 2026, Vasowatch will initiate a 300-patient clinical trial aimed at demonstrating meaningful reductions in hemorrhage rates while generating clinician usability data to support FDA Class II De Novo SaMD approval. 

Co-founded by Michael Milone, MD, PhD, Associate Professor of Pathology and Laboratory Medicine and Donald Siegel, MD, PhD, Professor of Pathology and Laboratory Medicine, at Penn Medicine, Verismo Therapeutics is developing a cell therapy platform, KIR-CAR, that reflects the design of killer immunoglobulin-like receptors (KIRs) for the treatment of solid tumors. In January 2025, the company dosed a first patient in the Phase 1 CELESTIAL-301 trial of SynKIR-310, moving the program into clinical evaluation across multiple r/r B-NHL subtypes. The company also presented clinical findings in an ASCO Trials-in-Progress poster for the STAR-101 SynKIR-CAR Phase 1 solid tumor trial. Verismo strengthened manufacturing readiness through a Miltenyi Biotec partnership to support lentiviral vector supply for SynKIR-110 and future scale-up. Scientific updates included presenting data at the Society of Immunotherapy of Cancer 2025 Annual Meeting highlighting SynKIR-110 anti-tumor activity and at the American Society of Hematology 2025 Annual Meeting suggesting SynKIR-310 may deliver stronger tumor control with lower cytokine release versus conventional CAR T. The company also earned Philadelphia Business Journal recognition as a Best Place to Work for a third consecutive year locally. 

Vetigenics is a clinical-stage animal health biotechnology company focused on developing antibody-based therapeutics for companion animals. The company was co-founded by Nicola Mason, BVetMed, PhD, Professor of Medicine and Pathobiology at Penn Vet; Don Siegel, MD, PhD, Professor of Pathology & Laboratory Medicine at Penn Medicine; and Adriann Sax, MBA, President and CEO. In 2025, Mason was named the Penn Center for Innovation’s Inventor of the Year. Vetigenics raised a $6 million seed round in January 2025 to advance its clinical-stage programs, accelerate preclinical candidates, and scale operations and manufacturing. The company added prominent industry leaders to its board to guide future growth: Chand Khanna, DVM, PhD, Stephen Lesser, JD, MBA, and Caleb Frankel, VMD. Vetigenics has achieved multiple clinical milestones across its oncology pipeline, with continued advancement of programs evaluating VGS-001 (anti-cCTLA-4) in combination with palliative radiation therapy for canine oral melanoma and VGS-002 (anti-cPD-1) as a monotherapy in dogs with urothelial carcinoma. In June 2025, the company dosed the first patient in its CHECKMATE K9 pilot study, a multi-site clinical trial evaluating dual immune checkpoint inhibition in dogs with solid tumors. In parallel, the company continues to expand its internal pipeline across cancer and chronic diseases while maintaining strategic partnerships with Merck Animal Health and Kyoritsu Seiyaku, reinforcing the strength of its antibody discovery platform.  

viTToria Biotherapeutics is a clinical-stage immunotherapy company developing autologous CAR T-cell therapies. Its proprietary Senza5™ platform technology leverages a five-day manufacturing process, disables the CD5 signaling pathway on engineered CAR T cells and bypasses CD5’s immunosuppressive effects to enhances stemness, durability, and efficacy. ViTToria was co-founded by Marco Ruella, MD, Associate Professor of Medicine in the Division of Hematology and Oncology at Penn Medicine, and Nicholas Siciliano, PhD, CEO. In December 2025, ViTToria presented first-in-human interim clinical data from its Phase 1 study of VIPER-101, a CD5-modulated autologous CAR-T therapy for patients with relapsed or refractory T-cell lymphoma, at the American Society of Hematology Annual Meeting. Early results suggested that Senza5 CAR5 has manageable toxicities, potent antitumor activity, robust and durable CAR-T expansion, and T-cell reconstitution at low doses of CAR T cells. In 2025, the company received the Startup of the Year Award from PCI and CEO Nicholas Siciliano also received the Science Center’s 2025 Commercialization Award, recognizing his contributions to commercializing innovative science and accelerating technology translation.  

Vivodyne is a biotechnology company pioneering the generation of predictive human data for new therapeutics before clinical trials. The company was co-founded by Dan Huh, Ph.D. Professor of Bioengineering at Penn Engineering, and Andrei Georgescu, Ph.D., CEO. Vivodyne’s platform integrates high-throughput, robotic platforms and complex human organ tissue models to produce human multi-omics data that improves target selection and safety profiling in drug discovery. In 2025, Vivodyne raised $40 million in Series A financing to expand its fully automated laboratory in South San Francisco and scale its AI-driven tissue data engine to meet the demand from pharmaceutical clients, driven by FDA and NIH guidance to significantly reduce reliance on less-predictive animal models.